Press Releases and Statements

(ORLANDO, Fla.) – The Consumer Healthcare Products Association (CHPA) today announced the appointment of Lisa Paley as Chair of its Board of Directors following its March board meeting held during the association’s annual Self-Care Leadership Summit (SLS) in Orlando, Florida.

CHPA released the below statement today following the U.S. Food and Drug Administration’s announcement that it will postpone its previously scheduled April 12 Nonprescription Drugs Advisory Committee meeting to reconsider the efficacy of oral phenylephrine.

(ORLANDO, Fla.) – The Consumer Healthcare Products Association (CHPA) today awarded its Ivan D. Combe Lifetime Achievement Award to longtime industry leader Jim Mackey at the opening session of its annual Self-Care Leadership Summit (SLS) in Orlando, Florida.

The Consumer Healthcare Products Association’s (CHPA) Educational Foundation today announced the launch of HealthInHand.org

The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone

CHPA President and CEO Scott Melville released the following statement in response to FDA concluding that existing regulatory framework for foods and dietary supplements are not appropriate for cannabidiol and that the agency intends to work with Congress on a new regulatory pathway:

CHPA applauds the passage of the Fiscal Year 2023 omnibus appropriations bill, which includes several CHPA-backed measures.

Manufacturers continue operating at maximum capacity to replenish children’s pain and fever reducers to meet current extraordinary demand. While there is not a widespread shortage and our member companies are continuously shipping out products to retailers to replenish supply as quickly as possible, we recognize that limited products on store shelves is frustrating for parents and caregivers.

The annual Monitoring the Future survey, conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting substance use in 2022 “held steady” following significant overall declines in 2021. This year’s findings are particularly meaningful following historic declines last year, especially since most teens returned to school, to extracurricular activities, and to other social engagements in 2022 after nearly two years of social distancing.

“As flu season begins, CHPA remains in close contact with our member companies who are currently meeting the elevated demand for safe and effective children’s pain reliever products.